Sandoz

Novartis AG's generic drug unit, Sandoz, is widely believed to be developing copies, too, but declines to comment.

Roche CEO Girds for First Biotech Generics Jeanne Whalen 2010

The Swiss drug maker Novartis, which unified its generic business in 2003 under the name Sandoz, recognized the consumer interest and business opportunity in generic drugs early on.

NYT > Home Page By NATASHA SINGER 2010

Sandoz, which is leading the market for biosimilars with a roughly 50% market share, ahead of Teva and U.S.-based Hospira Inc., expects the entire biosimilars business could reach more than $20 billion by 2020, up from a current $250 million.

Generics Companies Weigh In on Biological Drugs Goran Mijuk 2011

Profit margins at Novartis's generic-drug unit, called Sandoz, aren't as high as at the branded-drug unit, but sales were up 20% last year to $7.2 billion.

CEO Gambles on a Novartis Makeover 2008

Taking the idea further, there's Novartis NYSE: NVS , which has a fairly large generic drug business called Sandoz, but still gets much of its revenue from brand-name drugs and diagnostics.

unknown title 2011

Snyder: Mylan (NMS:MYL), Teva (NMS:TEVA) and Sandoz, which is owned by Novartis

Prospects For Generics Darken In Long Term - Yahoo! Finance 2010

Because in 1951, Sandoz, which is headquartered just a few hundred kilometers from Pont-Saint-Esprit, was the only place in the world where LSD was being produced.

Aspen Times - Top Stories 2010

Snyder: Mylan (NMS:MYL), Teva (NMS:TEVA) and Sandoz, which is owned by Novartis

Prospects For Generics Darken In Long Term - Yahoo! Finance 2010

But some experts question the generics companies' pricing rationale, saying the current constraints could even force larger generic producers such as Sandoz or Teva to rethink their operating models.

Generics Companies Weigh In on Biological Drugs Goran Mijuk 2011

Large companies such as Sandoz and even some innovators are leading the charge for biosimilars in developed markets.

Daily News & Analysis 2010